New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
10:07 EDTQTNT, FRSH, GPT, AWH, SLF, SABR, OILT, BKW, AEGR, SRC, PFE, MFC, ARES, TRXCOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aegerion (AEGR) initiated with a Sell at Goldman... Allied World (AWH) initiated with a Buy at CRT Capital... Ares Management (ARES) initiated with a Buy at BofA/Merrill... Burger King (BKW) initiated with an Equal Weight at Morgan Stanley... Gramercy Property Trust (GPT) initiated with a Buy at BofA/Merrill... Manulife Financial (MFC) initiated with a Buy at Canaccord... Oiltanking Partners (OILT) initiated with a Market Perform at Wells Fargo... Papa Murphy's (FRSH) initiated with a Buy at Jefferies... Pfizer (PFE) reinstated with a Buy at Goldman... Quotient (QTNT) initiated with a Buy at UBS... Sabre (SABR) initiated with a Buy at BofA/Merrill... Spirit Realty (SRC) initiated with a Neutral at BofA/Merrill... Sun Life Financial (SLF) initiated with a Buy at Canaccord... TransEnterix (TRXC) initiated with an Outperform at RBC Capital.
News For AEGR;AWH;ARES;BKW;GPT;MFC;OILT;FRSH;PFE;SABR;QTNT;SRC;SLF;TRXC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 10, 2014
08:31 EDTPFETeva announces launch of first generic Celebrex capsules in the U.S.
Teva Pharmaceutical Industries (TEVA) announces the launch of the first FDA-approved generic equivalent to Celebrex Capsules in the United States. Teva is offering 50, 100, 200, and 400 mg strengths of Celecoxib Capsules. Celebrex Capsules, marketed by Pfizer (PFE) had annual sales of approximately $2.56B in the United States, according to IMS data as of October 2014.
07:44 EDTBKWBurger King, Tim Hortons and Restaurant Brands report transaction results
Subscribe for More Information
07:38 EDTPFEMylan launches generic version of Pfizer's Celebrex capsules
Mylan (MYL) announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's (PFE) Celebrex Capsules, indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults. Celecoxib Capsules had U.S. sales of approximately $2.5B for the 12 months ending September 30, 2014.
06:58 EDTBKWBurger King upgraded at RBC Capital
Subscribe for More Information
06:43 EDTBKWBurger King upgraded to Outperform from Sector Perform at RBC Capital
Subscribe for More Information
December 9, 2014
16:37 EDTGPTGramercy Property Trust files to sell 45M shares of common stock
Morgan Stanley, BofA Merrill Lynch, J.P. Morgan and RBC Capital Markets are acting as joint book-running managers for the offering.
16:32 EDTGPTGramercy Property sees FY1 adj. FFO 45c-50c, may not compare with consensus (5c)
Subscribe for More Information
16:25 EDTGPTGramercy Property Trust increases dividend 43% to 5c
Subscribe for More Information
16:24 EDTGPTGramercy Property Trust to acquire $399M portfolio
Subscribe for More Information
14:28 EDTBKWTim Hortons shareholders approve proposed transaction with Burger King
Tim Hortons (THI) announced the company's shareholders have approved the transaction with Burger King Worldwide (BKW) that will create a new global quick service restaurant leader. Following approximately 99.2% approval of votes cast by THI shareholders, the two companies announced the name of the new parent company, Restaurant Brands International. The name reflects the new company's global scale and reach, which will include more than 18,000 restaurants operating in 100 countries under its two distinct, iconic brands. Upon close of the transaction, shares of Restaurant Brands International will be traded on the New York Stock Exchange and the Toronto Stock Exchange under the trading symbol "QSR." Units of Restaurant Brands International Limited Partnership are expected to trade on the Toronto Stock Exchange under the trading symbol "QSP." The transaction remains subject to customary closing conditions, including, among other things, approval and issuance of a final order of the Ontario Superior Court of Justice. The Ontario Superior Court of Justice hearing for the final order to approve the Arrangement is scheduled to take place on December 11, and completion of the Arrangement and related transactions is expected to occur on or about December 12.
12:22 EDTPFEPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:35 EDTBKWTim Hortons to host special shareholder meeting
Special Shareholder Meeting to vote upon the proposed arrangement with Burger King Worldwide is being held on December 9 at 10 am. Webcast Link
10:32 EDTPFEPfizer says in talks with FDA on path forward for Mylotarg
Pfizer announced the presentation of encouraging early- and late-stage data from clinical studies across several hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid leukemia. Among the highlights are results from several investigator-led, large, randomized studies evaluating the antibody-drug conjugate MYLOTARG in select adult AML populations. Research was presented at the 56th Annual Meeting of the American Society of Hematology in San Francisco, December 6-9. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs and chief medical officer for Pfizer Oncology, said “In particular, we are encouraged by the significant clinical evidence emerging from large randomized trials, such as AML-19 and ALFA-0701, demonstrating a positive impact of MYLOTARG when added to standard first-line treatment for patients with acute myeloid leukemia. We are engaging in discussions with the U.S. FDA and other health authorities to determine the best path forward for MYLOTARG. In addition, we plan to initiate an expanded access protocol for the therapy by the end of 2014 in the United States in patients with relapsed or refractory acute myeloid leukemia for whom there are no other treatment options.”
08:06 EDTSABRWyndham Hotel Group enters strategic technology partnership with Sabre
Subscribe for More Information
07:44 EDTPFEAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
10:00 EDTAWHOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:15 EDTAWHAllied World downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Allied World to Market Perform due to valuation.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
06:47 EDTBKWBurger King coverage resumed with a Buy at Goldman
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use